These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 17075653)

  • 1. Topical treatments for melasma and postinflammatory hyperpigmentation.
    Lynde CB; Kraft JN; Lynde CW
    Skin Therapy Lett; 2006 Nov; 11(9):1-6. PubMed ID: 17075653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin lightening preparations and the hydroquinone controversy.
    Draelos ZD
    Dermatol Ther; 2007; 20(5):308-13. PubMed ID: 18045355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New and experimental treatments of cloasma and other hypermelanoses.
    Picardo M; Carrera M
    Dermatol Clin; 2007 Jul; 25(3):353-62, ix. PubMed ID: 17662901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UK-based dermatologist online survey on the current practice and training in the management of melasma and postinflammatory hyperpigmentation.
    Ma Y; Millette D; Nalluri R; Yoo J
    Clin Exp Dermatol; 2020 Jun; 45(4):483-484. PubMed ID: 32061135
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of hyperpigmentation.
    Rossi AM; Perez MI
    Facial Plast Surg Clin North Am; 2011 May; 19(2):313-24. PubMed ID: 21763992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical agents used in the management of hyperpigmentation.
    Halder RM; Richards GM
    Skin Therapy Lett; 2004; 9(6):1-3. PubMed ID: 15334278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation.
    Grimes PE
    Cutis; 2004 Dec; 74(6):362-8. PubMed ID: 15663072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroquinone--what is its future?
    Toombs EL
    Dermatol Ther; 2007; 20(3):149-56. PubMed ID: 17803610
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Mehta RC; Garruto J; Gotz V; Sigler ML; Herndon JH
    J Drugs Dermatol; 2013 Mar; 12(3):s21-6. PubMed ID: 23545929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Herndon JH; Sigler ML; Gotz V; Garruto J; Mehta RC
    J Drugs Dermatol; 2012 Dec; 11(12):1478-82. PubMed ID: 23377519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperpigmentation: an overview of the common afflictions.
    Cayce KA; McMichael AJ; Feldman SR
    Dermatol Nurs; 2004 Oct; 16(5):401-6, 413-6; quiz 417. PubMed ID: 15624705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of hydroquinone-resistant melasma using topical methimazole.
    Malek J; Chedraoui A; Nikolic D; Barouti N; Ghosn S; Abbas O
    Dermatol Ther; 2013; 26(1):69-72. PubMed ID: 23384022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma.
    Tirado-Sánchez A; Santamaría-Román A; Ponce-Olivera RM
    Int J Dermatol; 2009 Aug; 48(8):893-5. PubMed ID: 19659872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperpigmentation and melasma.
    Rigopoulos D; Gregoriou S; Katsambas A
    J Cosmet Dermatol; 2007 Sep; 6(3):195-202. PubMed ID: 17760699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma.
    Monheit GD; Dreher F
    J Drugs Dermatol; 2013 Mar; 12(3):270-4. PubMed ID: 23545908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.
    Torok H; Taylor S; Baumann L; Jones T; Wieder J; Lowe N; Jarret M; Rich P; Pariser D; Tschen E; Martin D; Menter A; Weiss J
    J Drugs Dermatol; 2005; 4(5):592-7. PubMed ID: 16167418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
    Kaufman BP; Alexis AF
    J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma.
    Banihashemi M; Zabolinejad N; Jaafari MR; Salehi M; Jabari A
    J Cosmet Dermatol; 2015 Sep; 14(3):174-7. PubMed ID: 26177992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma.
    Nanda S; Grover C; Reddy BS
    Dermatol Surg; 2004 Mar; 30(3):385-8; discussion 389. PubMed ID: 15008866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.
    Sofen B; Prado G; Emer J
    Skin Therapy Lett; 2016 Jan; 21(1):1-7. PubMed ID: 27224897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.